Immuneering (NASDAQ: IMRX) is challenging conventional approaches of sustained inhibition in oncology by pioneering a novel class of therapies designed to outsmart cancer’s ability to adapt. With a proprietary platform...
Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the appointment of Mary-Elizabeth Gifford as chief of global impact. Prior to joining Clearmind, Gifford served as chief of global impact at Psyence BioMed, a...
Closely held PharmaJet has announced that its WHO prequalified Tropis ID Needle-free Injection System will be used exclusively in Pakistan’s latest polio immunization campaign to deliver vaccines to 1.8 million children...
CorMedix (NASDAQ: CRMD) has announced that its DefenCath antimicrobial catheter lock solution (CLS) has received innovative technology designation from closely held Vizient—a heathcare performance improvement company...
MAIA Biotechnology (NYSE American: MAIA) has announced highlights from a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany, showcasing its ongoing Phase 2 and Phase 3...
Closely held Amphista Therapeutics has announced the appointments of Dr. Lisa Butler as SVP of clinical operations, Dr. Alexandra Sevko as VP of translational science, and Nicola Lindsay as head of project and portfolio...
Nexalin Technology (NASDAQ: NXL) has announced that three independently published, peer-reviewed clinical studies collectively demonstrate the ability of its proprietary 15 mA Gen-2 Nexalin DIFS technology to improve...
Tenon Medical (NASDAQ:TNON) has announced that the FDA has granted 510(k) clearance for its SImmetry+ SI Joint Fusion System indicated for sacroiliac (SI) joint fusion for conditions including sacroiliac joint...
Tyler B. Evans, MD, MS, MPH, is a leading voice in global health equity, infectious disease, and humanitarian medicine. As co-founder, CEO, and chief medical officer of Wellness Equity Alliance (WEA), Dr. Evans has...
Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the publication of a patent application by the USPTO for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as...